Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
After finishing at $1.43 in the prior trading day, Verrica Pharmaceuticals Inc (NASDAQ: VRCA) closed at $0.80, down -44.23%. In other words, the price has decreased by -$44.23 from its previous closing price. On the day, 3.66 million shares were traded. VRCA stock price reached its highest trading level at $0.9389 during the session, while it also had its lowest trading level at $0.7472.
Ratios:
Our goal is to gain a better understanding of VRCA by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.23 and its Current Ratio is at 2.36.
On July 25, 2023, Needham Upgraded its rating to Buy which previously was Hold but kept the price unchanged to $10.
On March 22, 2023, Jefferies started tracking the stock assigning a Buy rating and target price of $10.Jefferies initiated its Buy rating on March 22, 2023, with a $10 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 26 ’24 when Hayes Christopher G. sold 26,183 shares for $2.66 per share. The transaction valued at 69,647 led to the insider holds 115,303 shares of the business.
Hayes Christopher G. sold 9,530 shares of VRCA for $23,444 on Aug 27 ’24. The CHIEF LEGAL OFFICER now owns 105,773 shares after completing the transaction at $2.46 per share. On Aug 26 ’24, another insider, Goldenberg Gary, who serves as the Chief Medical Officer of the company, sold 9,888 shares for $2.66 each. As a result, the insider received 26,302 and left with 97,862 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VRCA now has a Market Capitalization of 61442752 and an Enterprise Value of 14368328. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.69. Its current Enterprise Value per Revenue stands at 1.56 whereas that against EBITDA is -0.194.
Stock Price History:
Over the past 52 weeks, VRCA has reached a high of $11.41, while it has fallen to a 52-week low of $1.04. The 50-Day Moving Average of the stock is -52.43%, while the 200-Day Moving Average is calculated to be -84.94%.
Shares Statistics:
The stock has traded on average 980.86K shares per day over the past 3-months and 352340 shares per day over the last 10 days, according to various share statistics. A total of 42.41M shares are outstanding, with a floating share count of 26.07M. Insiders hold about 38.89% of the company’s shares, while institutions hold 43.59% stake in the company. Shares short for VRCA as of 1728950400 were 4533342 with a Short Ratio of 4.62, compared to 1726185600 on 3252865. Therefore, it implies a Short% of Shares Outstanding of 4533342 and a Short% of Float of 23.86.
